Prevention of recurrent hepatitis B post-liver transplantation (Q34936261)

5 August 2017

1 reference

title

Prevention of recurrent hepatitis B post-liver transplantation (English)

1 reference

5 August 2017

liver transplantation

1 reference

1 reference

1 reference

Anna S f Lok

1

1 reference

5 August 2017

1 October 2002

1 reference

5 August 2017

Liver Transplantation

1 reference

5 August 2017

8

1 reference

5 August 2017

10 Suppl 1

1 reference

5 August 2017

S67-73

1 reference

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

5 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35780

21 January 2018

Identifiers

DOI

10.1053/JLTS.2002.35780

1 reference

5 August 2017

1 reference

PubMed ID

12362302